1924 related articles for article (PubMed ID: 7923244)
21. Effect of hyperthermia on the antitumor actions of interferons.
Anjum A; Fleischmann WR
J Biol Regul Homeost Agents; 1992; 6(3):75-86. PubMed ID: 1283487
[TBL] [Abstract][Full Text] [Related]
22. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta.
Johns TG; Mackay IR; Callister KA; Hertzog PJ; Devenish RJ; Linnane AW
J Natl Cancer Inst; 1992 Aug; 84(15):1185-90. PubMed ID: 1378904
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of the antitumor effect of two types of murine recombinant interferons, (beta) and (gamma), against B16-F10 melanoma.
Sakurai M; Iigo M; Tamura T; Otsu A; Sasaki Y; Nakano H; Nakagawa K; Minato K; Ohe Y; Saijo N
Cancer Immunol Immunother; 1988; 26(2):109-13. PubMed ID: 3129191
[TBL] [Abstract][Full Text] [Related]
24. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
25. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz J; Brück J; Lenz J; Knop J; Tüting T
Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
[TBL] [Abstract][Full Text] [Related]
26. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Hedlund G
Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
[TBL] [Abstract][Full Text] [Related]
27. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
28. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
[TBL] [Abstract][Full Text] [Related]
29. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
30. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
31. Interferons-alpha/beta- and -gamma-resistant Friend cell variants exhibiting receptor sites for interferons but no induction of 2-5A synthetase and 67K protein kinase.
Coccia EM; Federico M; Romeo G; Affabris E; Cofano F; Rossi GB
J Interferon Res; 1988 Feb; 8(1):113-27. PubMed ID: 2966842
[TBL] [Abstract][Full Text] [Related]
32. Prevention of resistance to IFN-alpha antiproliferative activity: characterization of the effect of IFN-gamma and substitution for IFN-gamma by tumor necrosis factor.
Fleischmann CM; Stanton GJ; Fleischmann WR
J Biol Regul Homeost Agents; 1993; 7(2):50-7. PubMed ID: 8266815
[TBL] [Abstract][Full Text] [Related]
33. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
Rosenblum MG; Yung WK; Kelleher PJ; Ruzicka F; Steck PA; Borden EC
J Interferon Res; 1990 Apr; 10(2):141-51. PubMed ID: 2140395
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
[TBL] [Abstract][Full Text] [Related]
35. Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B-cell lymphoma.
Reid TR; Race ER; Wolff BH; Friedman RM; Merigan TC; Basham TY
Cancer Res; 1989 Aug; 49(15):4163-9. PubMed ID: 2787203
[TBL] [Abstract][Full Text] [Related]
36. Host STAT2/type I interferon axis controls tumor growth.
Yue C; Xu J; Tan Estioko MD; Kotredes KP; Lopez-Otalora Y; Hilliard BA; Baker DP; Gallucci S; Gamero AM
Int J Cancer; 2015 Jan; 136(1):117-26. PubMed ID: 24895110
[TBL] [Abstract][Full Text] [Related]
37. Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle.
Schiller JH; Horisberger MA; Bittner G; Carlin JM; Storer B; Byrne GI; Willson JK; Borden EC
J Biol Response Mod; 1990 Aug; 9(4):368-77. PubMed ID: 2395002
[TBL] [Abstract][Full Text] [Related]
38. Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon.
Moskophidis D; Battegay M; Bruendler MA; Laine E; Gresser I; Zinkernagel RM
J Virol; 1994 Mar; 68(3):1951-5. PubMed ID: 8107255
[TBL] [Abstract][Full Text] [Related]
39. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
Silagi S; Dutkowski R; Schaefer A
Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
[TBL] [Abstract][Full Text] [Related]
40. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice.
McKenna SD; Vergilis K; Arulanandam AR; Weiser WY; Nabioullin R; Tepper MA
J Interferon Cytokine Res; 2004 Feb; 24(2):119-29. PubMed ID: 14980076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
